OncoSec Medical Inc (ONCSQ)

[hschlauch]

Refractory is more inclusive. I think the phase 2 trial described on slide 21 is a registration study, i.e. one for which a NDA will be based.

Refractory includes initial nonresponders or patients who become nonresponsive, e.g. partial responders, to pembrolizumab. I estimate that the refractory population is approximately 90% of all unresectable stage III/IV metastatic melanoma patients who are treated with monotherapy pembrolizumab. I believe only approximately 10% of patients experience durable complete responses with monotherapy Keytruda in metastatic melanoma.